Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash & Equivalents (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Cash & Equivalents for 12 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 72.05% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Sep 2025, down 72.05%, and an annual FY2024 reading of $4.2 million, down 34.92% over the prior year.
  • Cash & Equivalents was $1.1 million for Q3 2025 at Arcadia Biosciences, down from $1.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $44.0 million in Q2 2021 and bottomed at $1.1 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $16.1 million, with a median of $13.5 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 133.33% in 2021, then plummeted 85.65% in 2024.
  • Year by year, Cash & Equivalents stood at $28.7 million in 2021, then fell by 28.03% to $20.6 million in 2022, then crashed by 68.43% to $6.5 million in 2023, then crashed by 34.92% to $4.2 million in 2024, then tumbled by 74.07% to $1.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for RKDA at $1.1 million in Q3 2025, $1.4 million in Q2 2025, and $3.2 million in Q1 2025.